[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_100":101},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","so93j09t03i3nv0mhvt368wej","revision",2,"title","ArriVent BioPharma 公布 firmonertinib 阶段1b试验结果","originalTitle","ArriVent BioPharma, Inc. (0001868279) (Filer)","summary","ArriVent BioPharma 公布 firmonertinib 在 Cancer Cell 发表的 FURMO-002 试验结果。试验编号 NCT05364073。该结果已作为 8-K 文件附件披露。","reason","source",{"_11":90,"_91":92,"_93":94,"_95":57,"_96":97,"_98":99},"links",{"_87":88,"_63":89},"publishedAt","2026-10-19T12:08:31.000Z","discoveredAt","2026-10-19T12:19:07.070Z","timelineAt","category","ai-products","tags",[81,82,83,84,85,86],"stockSymbols",[80],"score",32,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","firK4areh3Qk",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","3de958db-b77e-4e20-afa8-2bc3c844b7c3","ArriVent BioPharma firmonertinib 试验进展",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):\nOctober 19, 2026

ARRIVENT\nBIOPHARMA, INC.

(Exact name of registrant as specified in its\ncharter)

\n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware		001-41929		86-3336099
(State\n or other jurisdiction \n of incorporation)		(Commission\n File Number)		(IRS\n Employer \n Identification No.)

\n \n \n \n \n \n \n \n \n

18 Campus Boulevard, Suite 100

Newtown Square, PA

19073

(Address\n of principal executive offices)

(zip\n code)

Registrant’s telephone number, including\narea code: (628) 277-4836

N/A

(Former name or former\naddress, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n

Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)

\n\n

Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)

\n\n

Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))

\n\n

Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading \n Symbol(s)		Name of each exchange \n on which registered
Common Stock,\n $0.0001 par value per share		AVBP		The\n Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (17 CFR §240.12b-2).

Emerging Growth Company x

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

\n\n \n \n

Item 7.01

Regulation FD Disclosure.

On October 19, 2026, ArriVent BioPharma, Inc. issued a press release\nannouncing the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell. A copy of the\npress release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 7.01.

The information\nin this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange\nAct of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed\nincorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange\nAct, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit No.		Description
99.1		Press Release dated October 19, 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	ARRIVENT BIOPHARMA, INC.

	By:	/s/ Winston Kung
		Winston Kung
		Chief Financial Officer and Treasurer

Date: October\n19, 2026

","zhKind","complete","AVBP","公司与财报","财报","IPO","退市","停复牌","金融","aihot","/items/so93j09t03i3nv0mhvt368wej","https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792627200&sig=564cbec5bb9177d7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792627200&sig=034656c278a8477b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792627200&sig=23dae0083a3a8d72 96w","changelogVersion","2026-10-01T08:00"]